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Aim: The myocardial performance index (Tei index), plasma N-terminal pro B-type natriuretic peptide (NT-proBNP), and ischemiamodified albumin (IMA) were used to investigate the effect of obstructive sleep apnea syndrome (OSAS) on right ventricular function.
Materials and methods: Twenty-three patients diagnosed with OSAS (moderate or severe AHI > 15) by polysomnography at Karadeniz
Technical University Medical Faculty Chest Disease Clinic between September 2009 and September 2010 were included. The Tei index,
Nt-proBNP, and IMA were measured in all patients before CPAP treatment and 3 months after the diagnosis.
Results: Patients with OSAS had statistically significantly higher right ventricular Tei indices than the control group (P < 0.05). There
was no significant difference between the groups in terms of NT-proBNP or IMA values. The systolic blood pressure of the patient group
was significantly lower (P < 0.05) after CPAP treatment, but there was no difference in the Tei index, NT-proBNP, or IMA values.
Conclusion: We conclude that plasma NT-proBNP and IMA levels are not effective as the Tei index for showing myocardial damage
in patients with OSAS, and that these parameters are inadequate to show the effect of CPAP treatment on right ventricular myocardial
function.
Key words: Obstructive sleep apnea syndrome, Tei index, plasma N-terminal pro B-type natriuretic peptide, ischemia-modified albumin

1. Introduction
Obstructive sleep apnea syndrome (OSAS) is characterized
by repeated upper respiratory tract obstruction during
sleep and frequently by a decrease in oxygen saturation (1).
The most common symptoms in OSAS are severe snoring,
daytime sleepiness, and reported apnea. Complications
developing in OSAS patients during apnea and hypopnea
are pulmonary hypertension, systemic hypertension,
coronary insufficiency heart failure, left/right ventricular
(LV/RV) dysfunction, and arrhythmia (2,3).
The gold standard in mild or moderate–severe OSAS
with a cardiovascular or cerebrovascular disease is nasal
continuous positive airway pressure (nCPAP) treatment
(4,5). Using echocardiography, previous studies have
shown that this treatment has a positive effect on right
and left ventricular functions (6,7). We investigated the
correlation between the right ventricular Tei index and the
degree of OSAS.
N-terminal pro B-type natriuretic peptide (NTproBNP) is a marker of systolic and diastolic dysfunction
* Correspondence: foztuna@yahoo.com

released from both ventricles in association with volume
overload and distension (8). The literature contains
various studies evaluating NT-proBNP levels before and
after CPAP treatment, but this issue has conflicting results
(9–11). Ischemia-modified albumin (IMA) is formed as a
result of the normal human albumin N-terminal region
undergoing alteration during ischemia (12). Elevated IMA
showing myocardial ischemia has been identified not only
in coronary diseases, but also in pulmonary edema with
hypoxemia (13). Therefore, this marker may be expected to
be high in OSAS patients because of nocturnal hypoxemia.
This study investigated the effect of OSAS on global right
ventricular function using the myocardial performance
index (Tei index), plasma NT-proBNP, IMA, and nCPAP
on these parameters.
2. Materials and methods
Twenty-three adult (≥18 years) patients diagnosed with
moderate–severe OSAS by polysomnography who were
admitted to the Karadeniz Technical University Medical
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Faculty Chest Disease Clinic between September 2009 and
September 2010 and scheduled for nCPAP treatment were
included in this study. There were no exclusion criteria.
An age-matched control group of 23 individuals with
no excessive daytime sleep and an Epworth sleepiness
score of less than 10 was also established. Individuals in
either group who had a sleep-related respiratory disease
other than OSAS, diagnosed pulmonary disease, atrial
fibrillation, branch block or atrioventricular block, left
ventricular dysfunction (EF < 50%), ischemic or valvular
heart disease, or renal insufficiency (serum creatinine
> 2 mg/dL), or who were fitted with pacemakers, were
excluded.
Polysomnography tests were performed using an ALICE
Sleepware (Respironics Inc.) device at the KTU Medical
Faculty Sleep Unit under the supervision of a technician
with the patient in spontaneous sleep (Respironics Inc.).
PSG records were scored in 30-s epochs on the basis of
international classification of sleep disorders criteria
(AASM-2007) (14). CPAP titration was commenced at a
pressure of 4 cm H2O in 2nd-night records, and pressure
was gradually raised until no abnormal respiratory events
were observed. The most appropriate CPAP pressure
eliminating all abnormal respiratory events sleep was
determined for each patient during sleep. The use of CPAP
devices for at least 3.5 h per night and for 70% of nights
was accepted as effective use.
The Epworth sleepiness scale was completed for each
patient enrolled in the study. Total scores can range from
0 to 24; scores of 0–8 were evaluated as normal sleepiness,
9–12 as mild, 13–16 as average, and above 16 as severe.
Subjects with an Epworth sleepiness score of below 10
were enrolled as the control group.
Echocardiography, using 2-dimensional pulse-waved
Doppler and tissue Doppler imaging, was performed on
patients before beginning nCPAP treatment and at the
3rd month after treatment, and once during the study in
the control group. Examinations were performed at the
KTU Medical Faculty Department of Cardiology by a
cardiologist blinded to patients’ clinical and laboratory
data using a Vivid 7 (GE Vingmed Ultrasound, Horten,
Norway) echocardiography device with the patient in
the left lateral decubitus position. Doppler recording was
performed at a speed of 100 mm/s with simultaneous
single derivation ECG recording. All measurements were
taken at 3 consecutive cycles and the averages of these
were recorded. In order for the parameters not to be
affected by respiration and to be more consistent, Doppler
measurements were taken at the end of expirium. For
right ventricular systolic functions, ejection fraction (EF)
was calculated using Simpson’s method. Systolic artery
pressure was measured with the addition of mean right
atrial pressure to the transtricuspid gradient calculated
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using the maximum velocity of the tricuspid regurgitation
jet. Tricuspid flow was obtained with the pulsed wave
Doppler sample volume in the apical 4-chamber view
being placed on the ends of the tricuspid valve. In short
axis views, Doppler trace of flow was obtained from the
exit pathway of the right ventricle by placing the sample
volume immediately beneath the pulmonary valves. The
Tei index was calculated with the ejection process obtained
from the right ventricular exit pathway flow sample with
pulsed wave Doppler in the parasternal short axis view
subtracted from the tricuspid regurgitation flow duration
in the apical 4 chamber view (or the period from the end
of one diastolic flow at transtricuspid Doppler tracing to
the start of the next diastolic flow) being divided into the
remaining ejection duration.
Serum NT-proBNP tests were performed using
original kits on a Roche Cobas 6000 autoanalyzer
(proBNP II Cobas, Roche Diagnostics). The NT-proBNP
cutoff value was < 125 pg/mL. At IMA testing, reduced
cobalt to albumin binding capacity was measured using
the rapid and colorimetric method developed by Bar-Or
et al. (15). Values above 0.400 ABSU were regarded as low
cobalt binding and therefore exhibiting ischemia, while
values below 0.400 ABSU were regarded as nonischemic,
as recommended by those authors. Echocardiographic
parameters, NT-proBNP, and IMA concentration, were
analyzed before the start and at the 3rd month of nCPAP
treatment in the OSAS group and once at the beginning of
the study in the control group.
2.1. Statistical analysis
The chi-square test was used in the analysis of data
obtained by counting. The compatibility with normal
distribution of data obtained by measurement was
analyzed using the Kolmogorov–Smirnov test. Normally
distributed data were analyzed with Student’s t-test and
nonnormally distributed data with the Mann–Whitney U
test. Correlation between NT-proBNP, IMA, and Tei index
with AHI score, BMI TA, EF, PAB, and Epworth sleepiness
scale was investigated using Spearman correlation analysis.
Patient group pre- and posttreatment echocardiography
findings were analyzed using the McNemar test.
3. Results
Patients’ demographic characteristics are summarized
in Table 1. The prevalence of obesity and hypertension,
smoking year, BMI, and systolic blood pressure values were
higher in patients than in the control group. Data for basal
NT-proBNP, IMA, and echocardiographic parameters
are listed in Table 2. Although higher NT-proBNP
concentrations were determined in the patients than in
the control group, the difference was not significant. No
significant difference was determined between the groups
in terms of IMA values. The right ventricular Tei index
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Table 1. Basal characteristics of patients.
Patient (n = 23)
(Mean ± SD)

Control (n = 23)
(Mean ± SD)

P

Age (years)

53.6 ± 7.1

53.7 ± 6.5

0.983

Sex (F/M)

9/14

9/14

1.000

25.8 ± 1.7

<0.0005*

17 (73.91%)

1 (4.34%)

<0.0005*

13.1 ± 1.2

12.5 ± 0.09

0.127

133.7 ± 8.7

126.3 ± 5.7

0.002*

Diastolic blood pressure (mmHg)

81.3 ± 6.4

80.2 ± 3.5

0.288

Antihypertension treatment

15 (65%)

2 (8.7%)

<0.0005*

Diabetes mellitus

4 (17.4%)

0 (0%)

0.109

Variables

Body mass index (kg/m²)

34.8 ± 7.8

Obesity
Respiratory rate (/min)
Systolic blood pressure (mmHg)

£
£

†

Data are expressed as mean ± SD or number of patients (percentage)
Body mass index > 30 kg/m²
£
Systolic blood pressure ≥ 140 mmHg; diastolic blood pressure ≥ 90 mmHg
* P < 0.01
†

Table 2. Basal NT-proBNP, ischemia-modified albumin, and echocardiographic parameters.
OSAS (n = 23)
(Mean ± SD)

Control (n = 23)
(Mean ± SD)

9.17 ± 5.10

0.26 ± 0.54*

Tei index

0.323 ± 0.095

0.251 ± 0.010*

NT-proBNP (pg/mL)

89.3 ± 128.7

33.8 ± 21.5

IMA (ABSU)

0.493 ± 0.052

0.453 ± 0.092

Pulmonary arterial pressure (mmHg)

21.8 ± 5.9

22.1 ± 4.4

EF

63.6 ± 3.9

65 ± 1.4

Variables
Epworth sleepiness score

Data are expressed as mean ± SD
* P < 0.05

was significantly higher in the patients than in the control
group (0.32 ± 0.09 vs. 0.25 ± 0.01, P < 0.01). No significant
difference was determined between the 2 groups in terms
of pulmonary artery pressure or ejection fraction.
The basal and posttitration values of polysomnography
in patients are summarized in Table 3. Desaturation index,
AHI, duration of sleep time spent below 90%, and arousal
index were statistically significantly higher than basal
values. Oxygen level during sleep and minimum oxygen
levels were significantly lower than basal values. After
treatment, none of the patients reported complaints of
snoring, apnea, or daytime sleepiness.

Correlations between NT-proBNP, IMA, and Tei
index with BMI, TA, EF, PAB, oxygen level during sleep,
arousal index, and basal Epworth sleepiness scale are
shown in Table 4. A significant positive correlation
was determined between basal NT-proBNP values and
basal AHI (r = 0.442; P = 0.039). A significant positive
correlation was determined between basal IMA values
and basal desaturation index (r = 0.860; P = 0.025). A
significant negative correlation was determined between
basal oxygen level during sleep values and basal IMA level
(r = –0.598; P = 0.003). A significant negative correlation
was determined between basal minimum oxygen level and

395

ÖZTUNA et al. / Turk J Med Sci
Table 3. Basal and posttitration values in patient group.
Basal
(Mean ± SD)

After CPAP titration
(Mean ± SD)

AHI (events/h)

50.5 ± 26.6

3.9 ± 4.3*

Desaturation index

48.08 ± 24.2

2.50 ± 1.7*

Oxygen level during sleep (%)

89.13 ± 6.01

93.65 ± 2.05*

Duration of sleep time that was spent below 90% (min)

58.98 ± 106.56

1.76 ± 5.74*

Minimum oxygen levels (%)

74.43 ± 17.99

89.78 ± 6.99*

Arousal index (min)

29.85 ± 14.98

8.76 ± 6.32*

Variables

* P < 0.01
Table 4. Correlations between Tei index, NT-proBNP, and IMA, and apnea-hypopnea index, body mass index, blood pressure,
echocardiographic parameters, oxygen values, and arousal index.
Correlation coefficients

Variables

Tei index

NT-proBNP

IMA

Body mass index

–0.141

0.416

0.352

Systolic blood pressure

0.068

0.22

0.379

Diastolic blood pressure

0.047

0.191

0.198

Pulmonary arterial pressure

–0.109

0.279

0.25

Right ventricular ejection fraction

0.046

0.033

–0.024

—

0.242

–0.240

IMA

–0.24

0.412

—

NT-proBNP

0.242

—

0.412

AHI

–0.412

0.442*

0.348

Epworth sleepiness score

0.243

0.392

0.385

Arousal index

0.135

0.299

0.483*

Oxygen level during sleep

–0.246

–0.259

–0.598**

Desaturation index

–0.051

0.393

0.254

Tei index

Duration of sleep time that was spent below 90%

0.294

0.274

0.626**

Minimum oxygen levels

–0.061

–0.229

–0.591**

* P < 0.05 ,

**P < 0.01

baseline IMA level (r = –0.591; P = 0.003). A significant
positive correlation was determined between basal IMA
values and baseline duration of sleep time spent below
90% (r = 0.6.26; P = 0.001).
Although posttreatment diastolic blood pressure (81.3
± 6.4 vs. 79.8 ± 4.1 mmHg), posttreatment NT-proBNP
(89.3 ± 128.7 vs. 71.7 ± 79.8 pg/mL), posttreatment IMA
(0.49 ± 0.05 vs. 0.51 ± 0.08 ABSU), posttreatment Tei index
(0.32 ± 0.09 vs. 0.31 ± 0.08), and posttreatment pulmonary
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arterial pressure (21.8 ± 5.9 vs. 20.3 ± 5.8 mmHg) were
decreased, these differences did not reach statistically
significant levels compared to basal values. There was no
change in right ventricular ejection fraction (63.6 ± 3.9 vs.
63.5 ± 3.5) after treatment. Systolic blood pressure (133.7
± 8.7 vs. 130.4 ± 6.7 mmHg) and heart rate (78.3 ± 3.7 vs.
75.4 ± 2.8/min) decreased significantly compared to basal
values (Figures 1 and 2).
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85.00

P = 0.003

P = 0.001

80.00
Heart rate (beat/min)

Systolic blood pressure (mmHg)

140.00

130.00

75.00

70.00

†

120.00

65.00

Before treatment

After treatment

Before treatment

After treatment

Figure 1. Basal and systolic blood pressure values of patients.

Figure 2. Basal and posttreatment heart rate values of patients.

4. Discussion
The right ventricle structure and function in OSAS patients
is negatively affected by several factors, including obesity,
elevations in the intrathoracic negative pressure related
to apneic events, and nocturnal increases in pulmonary
vascular resistance. All of these factors have been related to
impaired right ventricular filling and diastolic dysfunction
(16–18). Obesity is an important risk factor for the
development of OSAS. The Cleveland Family Study has
shown that an increase in bodyweight over time increases
the risk for and accelerates the progression of OSAS (19).
In our study, the patient group was overweight and had
a high body mass index. We found that the oxygen levels
during sleep and the minimum oxygen levels of patients
were low. İnönü et al. compared 71 patients with OSAS
and 12 with complex sleep apnea syndrome (SAS) (20).
The study showed that the level of oxygen saturation was
lower in the complex SAS group than in the OSAS group.
CPAP is the most effective treatment for the prevention
of cardiac complications in OSAS patients. Bayram et
al. compared 28 moderate–severe OSAS patients with
18 control cases. According to parameters determined
by tissue Doppler echocardiography, right ventricular
systolic and diastolic dysfunction was present in the OSAS
group, and there was an improvement in these parameters
after 6 months of CPAP treatment (21). Dursunoğlu et al.
included 18 moderate–severe OSAS patients in a study
intended to investigate the effects of CPAP treatment
on right ventricular myocardial performance. Patients
underwent echocardiography at the beginning of the
study and after 6 months of CPAP treatment. At the end
of the study, the right atrial and ventricular end diastolic
diameters were unchanged after treatment, while the right

ventricular free wall diameter and right ventricular Tei
index were decreased in comparison to initial levels (7).
The mean right ventricular Tei index our OSAS patients
was 0.32 ± 0.09, and 0.25 ± 0.01 in the control group; it
was higher in the former group, in accordance with other
studies. Patients’ mean right ventricular Tei index at
the start of our study was 0.32 ± 0.09, and although this
declined to 0.31 ± 0.08 after treatment, this decrease was
not significant. In addition, the patients in other studies
were evaluated with echocardiography after 6 months of
CPAP treatment, while in the present study patients were
evaluated after 3 months of CPAP treatment. Patients
with hypertension were also included in our study, and
our study period was shorter than those of other studies,
which might be the reason for the lack of any significant
difference in right ventricular Tei index values after CPAP
treatment.
In a multicenter, double-blinded, randomized
study by Cantolla et al., the effect of CPAP on systemic
hypertension was investigated with CPAP given to 169 out
of 340 OSAS patients with BMI > 15, and placebo to the
other 171. At the end of the study, a 2.1 mmHg decrease in
mean systolic blood pressure and a 1.33 mmHg decrease
in diastolic blood pressure were observed in the 3-month
CPAP treatment group (22). Our patients’ mean systolic
blood pressure before treatment was 133.7 ± 8.7 mmHg,
compared to 130.4 ± 6.7 mmHg after CPAP. As with other
studies, we found a significant decrease in systolic blood
pressure in OSAS patients after CPAP treatment. Our
patients’ mean initial diastolic blood pressure was 81.3
± 6.4 mmHg. Despite contracting to 79.8 ± 4.1 mmHg
after CPAP treatment, in contrast to other studies, the
difference was not statistically significant. We think that
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the reasons for this difference might be the presence of
systemic hypertension in all cases in the studies examining
the effects of CPAP on systemic hypertension, and the
greater number of cases in these studies than in our study.
Studies have shown that BNP rises in various cardiac
conditions, including coronary insufficiency, coronary
artery disease, and cardiac hypertrophy. Left ventricular
capacity decreases in parallel to increased BNP and has
been correlated with a poor prognosis (23). Maeder et
al. reported that a high serum NT-proBNP level in OSAS
patients is an appropriate marker for cardiovascular system
injury independent of increased oxygen consumption (24).
Koga et al. compared 27 moderate–severe OSAS patients
with 22 controls; the left ventricle Tei index was higher
in the OSAS group, but they determined no significant
difference between plasma BNP levels. Moreover, that
study determined that there was a significant decrease in
OSAS patients’ Tei index and BNP values after 3 months
of CPAP treatment (6). Kita et al. determined that plasma
BNP levels rose throughout sleep in OSAS patients, but
that this was not correlated with patients’ clinical and
polysomnographic parameters. They also observed that
CPAP treatment reduced BNP levels (25). Tasci et al.
reported no significant difference between hypertensive
and normotensive OSAS patients’ plasma NT-proBNP
levels, but showed that NT-proBNP levels declined with
CPAP treatment (26). Similarly to Kita et al., Hübner et
al. showed no significant correlation between serum
NT-proBNP levels and AHI, BMI, mean and minimal
saturation, left ventricle ejection fraction, and left
ventricular Tei index. Contrary to other studies, however,
they showed that there was no change in NT-proBNP level
after CPAP treatment (10,25). Similarly, Çifçi et al. failed to
establish a correlation between OSAS severity and plasma
NT-proBNP levels, and reported that NT-proBNP levels
were not altered with CPAP treatment (11). In the light of
these few studies with conflicting results, it is still unclear
what kind of correlation exists between CPAP treatment
and serum BNP levels. The mean NT-proBNP level in our
OSAS patients was 89.3 ± 128.7 pg/mL, and 33.8 ± 21.5
pg/mL in the control group. In addition, and similarly
to Hübner and Çifçi’s studies, although mean serum
NT-proBNP values fell to 71.7 ± 79.8 pg/mL after CPAP
treatment, this decrease was not statistically significant.

Elevated IMA levels have been shown in such ischemic
events and hypoxemia (13,27,28). Previous studies have
shown that IMA reflects the magnitude and duration
of ischemia induced during percutaneous coronary
intervention and exercise test for coronary syndrome,
and that it is a sensitive marker for the identification of
acute cardiac ischemia (29–32). The most important
characteristic that differentiates IMA from other cardiac
ischemia markers is that it increases in the early phase.
Therefore, IMA could be considered to be an applicable
diagnostic marker for OSAS. Our scan of the literature
revealed no publications regarding IMA levels in OSAS
cases. No significant difference was determined in our
study between the IMA levels of the OSAS patients and
those of the control group. OSAS patients’ IMA values did
not change with CPAP treatment. However, the negative
correlation between baseline oxygen level during sleep
values, minimum oxygen level, and baseline IMA level was
significant. From the point of view of these relationships,
IMA could be a hypoxemic marker in OSAS patients.
In the light of existing findings, our study supports
the idea that plasma NT-proBNP and IMA levels are
not as sensitive as the Tei index in showing myocardial
injury developing in OSAS, and that these parameters are
inadequate in determining the effect of CPAP treatment
on right ventricular myocardial function. The limited
number of cases and the absence of an OSAS patient
group are the main limitations of the present study.
However, since patients diagnosed with OSAS without
any cardiac insufficiency were included in our study, the
patient population is a more appropriate one in terms of
investigating the cardiac effects of intermittent hypoxia
compared to those of other studies. In the light of the study
data, we think that more research on different markers is
needed to show cardiac injury developing in OSAS patients
before clinical findings develop.
Acknowledgements
The authors thank Assist Prof Dr. Yasin Abul and Carl
Nino Rossini for the English correction of the manuscript.
The authors thank Prof Dr Murat Topbaş from Karadeniz
Technical University, Medical School, Department of
Public Health, for the graphics.

References
1.

Golbidi S, Badran M, Ayas N, Laher I. Cardiovascular
consequences of sleep apnea. Lung 2012; 190: 113–32.

2.

Phillips B. Sleep-disordered breathing and cardiovascular
disease. Sleep Med Rev 2005; 9: 131–40.

3.

Karaşen RM, Çiftçi B, Acar B, Yalçın AA, Güven SF. Heart rate
recovery in patients with obstructive sleep apnea syndrome.
Turk J Med Sci 2012; 42: 964–9.

398

4.

Sullivan CE, Issa FG, Berthon-Jones M, Eves L. Reversal
of obstructive sleep apnoea by continuous positive airway
pressure applied through the nares. Lancet 1981; 1: 862–6.

5.

Hedner J, Darpö B, Ejnell H, Carlson J, Caidahl K. Reduction
in sympathetic activity after long-term CPAP treatment in
sleep apnoea: cardiovascular implications. Eur Respir J 1995;
8: 222–9.

ÖZTUNA et al. / Turk J Med Sci
21.

Bayram NA, Çiftçi B, Bayram H, Keleş T, Durmaz T, Akçay M
et al. Effects of continuous positive airway pressure therapy
on right ventricular function assessment by tissue doppler
imaging in patients with obstructive sleep apnea syndrome.
Echocardiography 2008; 25: 1071–8.

22.

Munagala VK, Burnett JC, Redfield MM. The natriuretic
peptides in cardiovascular medicine. Curr Probl Cardiol 2004;
29: 707–69.

Duran-Cantolla J, Aizpuru F, Montserrat JM, Ballester
E. Continuous positive airway pressure as treatment for
systemic hypertension in people with obstructive sleep apnea:
randomized control trial. BMJ 2010; 341: 1–9.

23.

9.

Hoekema A, Voors AA, Wijkstra PJ. Effects of oral appliances
and CPAP on the left ventricle and natriuretic peptides. Int J
Cardiol 2008; 128: 232–9.

Wang TJ, Larson MG, Levy D, Benjamin EJ. Plasma natriuretic
peptide levels and the risk of cardiovascular events and death.
N Engl J Med 2004; 350: 655–63.

24.

10.

Hübner N, Mokhtari N, Freitag S. NT-pro BNP is not elevated
in patients with obstructive sleep apnea. Respiratory Medicine
2008; 102: 134–42.

Maeder MT, Amman P, Rickli H, Schoch OD. N-terminal proB-type natriuretic peptide and functional capacity in patients
with obstructive sleep apnea. Sleep Breath 2008; 12: 7–16.

25.

11.

Çifçi N, Uyar M, Elbek O. Impact of CPAP treatment on
cardiac biomarkers and pro-BNP in obstructive sleep apnea
syndrome. Sleep Breath 2010; 14: 241–4.

Kita H, Ohi M, Chin K, Noguchı T, Otsuka N. The nocturnal
secretion of cardiac natriuretic peptides during obstructive
sleep apnea and its response to therapy with nasal continuous
positive airway pressure. J Sleep Res 1998; 7: 199–207.

26.

Sinha MK, Roy D, Gazze DC. Role of “ischaemia modified
albumin”, a new biochemical marker of myocardial ischaemia,
in the early diagnosis of acute coronary syndromes. Emerg
Med J 2004; 21: 29–34.

Tasci S, Manka R, Scholtyssek S, Lentini S. NT-pro BNP
in obstructive sleep apnea syndrome is decreased by nasal
continuous positive airway pressure. Clin Res Cardiol 2006;
95: 23–30.

27.

Peacock F, Morris DL, Anwaruddin S, Christenson RH,
Collinson PO. Meta-analysis of ischemia-modified albumin
to rule out acute coronary syndromes in the emergency
department. Am HeartJ 2006; 152: 253–62.

28.

Mentese A, Mentese U, Turedi S, Gunduz A, Karahan SC,
Topbas M. Effect of deep vein thrombosis on ischaemiamodified albumin levels. Emerg Med J 2008; 25: 811–4.

29.

Quiles J, Roy D, Gaze D, Garrido IP, Avanzas P, Sinha M et al.
Relation of ischemia-modified albumin (IMA) levels following
elective angioplasty for stable angina pectoris to duration of
balloon-induced myocardial ischemia. Am J Cardiol 2003; 92:
322–4.

30.

Roy D, Quiles J, Aldama G, Sinha M, Avanzas P, ArroyoEspliguero R et al. Ischemia modified albumin for the
assessment of patients presenting to the emergency department
with acute chest pain but normal or non-diagnostic 12-lead
electrocardiograms and negative cardiac troponin T. Int J
Cardiol 2004; 97: 297–301.

31.

Kalay N, Cetinkaya Y, Basar E, Muhtaroglu S, Ozdogru I, Gul
A et al. Use of ischemia-modified albumin in diagnosis of
coronary artery disease. Coron Artery Dis 2007; 18: 633–7.

32.

Kanko M, Yavuz S, Duman C, Hosten T, Oner E, Berki T.
Ischemia-modified albumin use as a prognostic factor in
coronary bypass surgery. J Cardiothorac Surg 2012; 7: 3.

6.

Koga S, Ikeda S, Urata J. Effect of nasal continuous positive
airway pressure in men on global left ventricular myocardial
performance in patients with obstructive sleep apnea
syndrome. Am J Cardiol 2008; 101: 1796–1800.

7.

Dursunoğlu N, Dursunoğlu D, Özkurt S. Effects of CPAP on
right ventricular myocardial performance index in obstructive
sleep apnea patients without hypertension. Respiratory
Research 2006; 7: 22–30.

8.

12.

13.

Turedi S, Gunduz A, Mentese A. Value of ischemia-modified
albumin in the diagnosis of pulmonary embolism. Am J Emerg
Med 2007; 25: 770–3.

14.

Iber C, Ancoli-Israel, Chesson A, Quan SF. The AASM
Manual for the Scoring of Sleep and Associated Events: Rules,
Terminology and Technical Specifications,1st ed., American
Academy of Sleep Medicine, Westchester, IL, 2007.

15.

Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin
binding and its potential as a marker of myocardial ischemia—a
preliminary report. J Emerg Med 2000; 19: 311–15.

16.

Gami AS, Pressman G, Caples SM, Kanagala R, Gard JJ, Davison
DE et al. Association of atrial fibrillation and obstructive sleep
apnea. Circulation 2004; 110: 364–7.

17.

Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Javier
Nieto F et al. Sleep-disordered breathing and cardiovascular
disease: cross-sectional results of the Sleep Heart Health Study.
Am J Respir Crit Care Med 2001; 163: 19–25.

18.

Shamsuzzaman AS, Gersh BJ, Somers VK. Obstructive sleep
apnea: implications for cardiac and vascular disease. JAMA
2003; 290: 1906–1914.

19.

Tishler PV, Larkin EK, Schluchter MD, Redline S. Incidence of
sleep-disordered breathing in an urban adult population: the
relative importance of risk factors in the development of sleepdisordered breathing. JAMA 2003; 289: 2230–7.

20.

İnönü H, Çiftçi TU, Köktürk O. The clinical and
polysomnographic features in complex sleep apnea syndrome.
Turk J Med Sci 2010; 40: 693–9.

399

